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Colorectal cancer (CRC) is a disease without evident clinical symptoms in early stages, leading to late 
diagnosis and disease management. Current diagnostic and prognostic tools require invasive procedures 
and circulating molecular biomarkers fail to have optimal sensitivity and specificity. Circulating 
biomarkers with high clinical performance may be valuable for early diagnosis and prognosis of CRC. 
The purpose of this review was to investigate the application of circulating cell-free DNA (ccfDNA) in 
CRC diagnosis and prognosis and the analytical methods used in blood samples in articles published 
between 2005 and 2016. Based on specific inclusion and exclusion criteria, 26 articles were selected. 
Most studies used ccfDNA quantification as the molecular biomarker. The analytical method was mainly 
based on the quantitative polymerase chain reaction (qPCR). Biomarkers based on aberrantly methylated 
genes (n=6) and ccfDNA integrity/fragmentation (n=2) were also used for the CRC diagnosis. The CRC 
prognosis used the detection of oncogene mutations, such as KRAS and BRAF, in ccfDNA. Significant 
differences were found in variables among the studies revealing potential bias. ccfDNA quantification as 
a diagnostic biomarker for CRC has promising results but it lacks clinical specificity since other diseases 
present a similar increase in ccfDNA content. However, increasing research in the epigenomic field can 
lead the way to a clinically specific biomarker for the CRC early diagnosis. As for the analytical method, 
qPCR and derivatives seem to be a perfectly valid technique. The use of ccfDNA quantification in CRC 
prognosis seems promising. The attempt to use the ccfDNA quantification in clinical practice may reside 
in the prognosis using a qPCR technique.
Keywords: Colorectal Neoplasms/diagnosis. Colorectal cancer. Circulating cell-free DNA. ccfDNA. 
Prognosis. Diagnosis. Biomarkers. Neoplastic Cells/circulating.
INTRODUCTION
Cancer is one of the leading causes of morbidity 
and mortality with 14 million new cases and 8.2 million 
related deaths in 2012 (Ferlay et al., 2015). Colorectal 
cancer (CRC) is the third most prevalent type of cancer 
with 1.4 million (9.7 %) cases diagnosed worldwide each 
year (Ferlay et al., 2015).
The CRC is a solid tumor with slow progression 
over the years without evident clinical symptoms in early 
stages, which causes difficulty for an early diagnosis. 
CRC symptoms include an anemia of unknown origin, 
changes in the intestinal habits (diarrhea or constipation), 
abdominal discomfort with flatulence or cramps and blood 
on the feces (INCA, 2016; American Cancer Society, 
2016). Usual diagnostic and screening exams for the 
CRC are based on blood tests in stool samples, such as the 
guaiac-based fecal occult blood test (gFOBT), the fecal 
immunochemical test (FIT) and the stool DNA test, and on 
an imaging analysis such as sigmoidoscopy, colonoscopy, 
double-contrast barium enema and the CT colonoscopy 
and tumor biopsy derived from colonoscopy (American 
Cancer Society, 2016).
Analysis of tumor markers in plasma, such as 
carcinoembryonic antigen (CEA), cancer antigen (CA) 
19-9 and tissue polypeptide specific antigen (TPS) have 
been used for CRC management. The CEA, is a high 
molecular weight glycoprotein involved in cell adhesion, 
apoptosis and immunity, used in clinical practice. The 
CA 19-9 is a glycoprotein with high molecular weight 
released to the blood and is observed in gastrointestinal 
tract tumors. TPS is a single conjugated polypeptide chain 
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formed in the S and G2 phase of the molecular cycle and 
released to cells after mitosis (Swiderska et al., 2014). 
Unfortunately, these biomarkers did not demonstrate 
sufficient sensitivity and specificity. There is an urgent 
search for more sensitive and specific biomarkers for CRC 
(Swiderska et al., 2014; Nicholson et al., 2015).
Molecular biomarkers in blood samples are proposed 
for diagnosis and prognosis of the CRC, such as circulating 
free DNA (ccfDNA) (Yörüker et al., 2016). ccfDNA is the 
DNA present in plasma directly released from viable cells 
or activated macrophages, or released during cell death 
by mechanisms of the apoptosis or necrosis (Yörüker et 
al., 2016) (Figure 1). Moreover, tumor cells also release 
significant amounts of DNA in the blood circulation, 
which is incorporated into the circulating DNA pool 
(Diaz Jr., Bardeli, 2014). The measurement of ccfDNA 
has been proposed as a biomarker of the tumor burden 
and it is potentially useful for diagnosis, prognosis and 
therapy management of the CRC (Diaz Jr., Bardeli, 2014). 
Moreover, the analysis of CRC mutations in circulating 
DNA could represent an “alternative biopsy”, mainly 
for therapy monitoring and tumor recurrences. (Diaz Jr., 
Bardeli, 2014).
Aberrant DNA methylation (metDNA) has also 
been found to be associated with the CRC disease (Lao, 
Grady, 2011). Hypermethylation of the CpG islands 
located at the promoter region causes gene silencing, while 
hypomethylation increases gene transcription. Studies 
have already verified a few genes frequently methylated 
in the CRC (Lao, Grady, 2011). There might be a clinical 
application for the detection of those methylated genes. 
Current clinical prognosis biomarkers include 
microsatellite instability (MSI) and the study of 
mutations in oncogenes. MSI status can be verified by 
immunohistochemistry and by PCR amplification (Morris, 
Kopetz, 2013). High MSI indicates a good prognostic 
correlating to the initial stages of the disease, smaller 
recurrence rates after resection of the primary tumor 
(Morris, Kopetz, 2013). 
The CRC-associated mutations within the proto-
oncogene KRAS are the most studied. KRAS mutations 
lead to an activated state of the RAS proteins, which 
stimulate the proliferation by two distinct pathways 
PI3K/PTEN/AKT and RAF/MEK/ERK. These mutations 
are present in stage IV of the disease and in different 
metastases representing an unfavorable survival outcome 
(Morris, Kopetz, 2013). In addition, mutations in KRAS 
affect the effectiveness of recent anti-epidermal growth 
factor receptor (EGFR) therapies (Morris, Kopetz, 2013).
Mutations in the oncogene BRAF lead to constitutive 
activation of the MAPK pathway. Consequently, BRAF 
mutations relate to a worse prognosis indicating as well 
non-responsiveness to anti-EGFR therapies (Morris, 
Kopetz, 2013). Mutations in the oncogene PIK3CA lead 
to apoptosis resistance, cell proliferation and promotion 
of cell migration. However, the relationship of PIK3CA 
mutations with the prognosis is still unclear. Mutations 
on the tumor suppression gene TP53 also have limited 
relevant data on CRC disease management. 
Considering the potential relevance of ccfDNA for 
CRC management, this review approaches the findings 
of clinical studies published between 2005 and 2016 that 
investigated the application of ccfDNA on diagnosis and 
prognosis of CRC and the analytical methods used for 
ccfDNA detection in blood samples. More diagnostic 
studies were found in comparison to prognostic ones. 
Perhaps this is due to the fact that the early detection 
of malignant tumors is a more relevant need in clinical 
practice, but also, prognostic studies, especially the 
prospective ones, required a longer time of patient 
follow-up, which implicates in more costs and work 
demand.
The majority of studies were prospective. The 
bias that retrospective information provides enables the 
preference for a prospective study design, since: only 
larger tumors grant sufficient tissue for storage; and there 
is less control of the storage conditions of both tissue and 
plasma, leading to irregular data (Duffy, Crown, 2014). 
Other uses for ccfDNA CRC management were 
not discussed in this review. Particularly. the use of 
ccfDNA for treatment follow-up (popularly known as 
liquid biopsy) has an important clinical utility since there 
are major mutations related to treatment response. For 
instance, the presence of KRAS mutations indicates low 
FIGURE 1 - Schematic mechanisms of release and ccfDNA 
characteristics.
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response to treatment with antiEGFR drugs (cetuximabe, 
panitumumabe) and these mutations may occur at any time 
of disease progression. Analyzing this mutation in tumor 
tissue is a necessity but also an inconvenience. For that 
reason, the detection of a KRAS mutation in ccfDNA is a 
way out of an invasive procedure, enabling a closer follow-
up with blood exams in tighter windows. Unfortunately 
this was not comprised among the objectives of this review 
to avoid an over extensive research.
ccfDNA in CRC diagnosis
Studies based on diagnostic molecular biomarkers 
for CRC (n=17) can be divided into main groups of 
biomarkers: ccfDNA quantification, metDNA (commonly 
methylated genes in CRC) and ccfDNA integrity (ccfDNA 
fragmentation).
The choice of a biological sample in most studies 
(n=21) was plasma, whereas only 5 studies used serum. 
Such a choice might be explained by the differences in 
the processing of plasma and serum samples. To obtain 
serum, a clotting process of the whole blood is necessary 
before separating serum from the blood cells. The lysis of 
white blood cells can occur during the clotting process, 
leading to a higher quantity of ccfDNA contaminated with 
genomic DNA (El Messaoudi et al., 2013). Therefore, 
it is not ideal to use serum as a biological sample when 
analyzing the total amount of ccfDNA. As expected, 
studies that used serum had higher ccfDNA quantification 
values in both control and CRC patients. 
Basic requirements to validate proper diagnostic 
biomarkers are sensitivity and specificity, and accuracy 
obtained through a robust ROC curve (used to set cut-off 
points) (Duffy, Crown, 2014). 
ccfDNA quantification biomarkers
As for analytical methods, quantitative PCR (qPCR) 
was the method used to measure ccfDNA levels in 4 out of 
9 CRC studies. The remaining studies quantified ccfDNA 
by UV spectrophotometry (n=1), fluorimetry (n=2), and 
color-based (DipStick) (n=1) methods (Table I). 
All studies that measured ccfDNA levels as a 
biomarker for CRC diagnosis (n=9) had a prospective 
design (Table II). These studies selected 20-223 CRC 
patients and 20-99 healthy subjects. Tumor staging varied 
from primary (n=4) to stage IV and metastatic (n=5). 
Most of the studies (n=7) used plasma whereas 
only two studies used serum to extract ccfDNA. DNA 
was extracted using Qiagen (n=6) or Applied Biosystems 
(n=1) technologies, which are silica-based nucleic acid 
purification kits for different types of biological samples. 
One study used DNA-Technology to isolate DNA by 
a universal precipitation-based method, and one study 
analyzed ccfDNA directly from serum samples (Table II).
Overall, ccfDNA quantification ranged from 25-868 
ng/ml. The two studies that used serum had higher ccfDNA 
quantification values in CRC patients: 868 (22 – 3922) 
ng/ml (median) for stage IV CRC patients and 798 ± 409 
ng/mL (mean) for primary CRC patients (Table II). In 
contrast, the higher value obtained with plasma samples 
was 437 (IQR 191-750) ng/ml (median) with primary and 
recurrent CRC patients (Table II).
The majority of studies (n=6) was able to demonstrate 
a significant difference in ccfDNA quantification between 
cancer patients and healthy subjects (Table II). 
Based on qPCR methods for ccfDNA quantification, 
two studies found low ccfDNA levels. In CRC patients, 
the values were 26 ng/ml (Moulière et al., 2014) and 29.45 
± 12.24 ng/ml (Kondratov et al., 2014) while two others 
(Frattini et al., 2008; Frattini et al., 2006) reported high 
ccfDNA concentrations (437 (IQR 191-750) ng/ml and 
495.7 (100-1750) ng/ml, respectively (Table II). 
One study used different values for quantification 
(alleles/ml) and therefore had different quantitative results 
17900 (800 – 4618400) alleles/ml for CRC patients. Still 
there was a significant difference between cancer patients 
and controls in this study (p<0.0001) (Table II).
Three out of 9 studies presented data on sensitivity 
and specificity. The ROC curve analysis with AUC values 
ranged from 0.84-0.94 (Table II). As for cut-off values, 
Czeiger et al. (2011) used a cut-off of 841 ng/ml leading to 
a sensitivity and specificity of 42% and 94%, respectively, 
and Kondratov et al. (2014) had 17.7 ng/ml as cut-off value 
leading to the detection of 8 out of 20 CRC cases. 
S tud ies  have  demons t ra ted  tha t  cc fDNA 
quantification differs among tumor stages and metastatic 
CRC has the highest values (Cassinotti et al., 2013; Lin 
et al., 2014). Therefore, metastatic CRC represents a bias 
in diagnostic parameters based on ccfDNA quantification, 
since metastatic CRC values are more likely to differ 
from healthy subjects and the main clinical need is early 
diagnosis. In this review, 4 out of 8 studies on the CRC 
diagnosis limited their population to only metastatic CRC 
and one of them had the highest AUC value observed in 
this review of 0.949 (Table II). In contrast, Czeiger et al. 
(2011) obtained a ROC curve AUC value of 0.84 with 
primary CRC patients, conceptually a more reliable and 
clinically useful result.
Among the biomarkers analyzed in this review, 
ccfDNA quantification had consistent results, both for the 
diagnosis and prognosis analysis. Moreover quantitative 
PCR as the analytical method seems to be adequate for 
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both purposes. However, ccfDNA quantification is yet 
to be proven clinically specific, since elevated levels 
of ccfDNA can be observed in other diseases (Wang, 
Chen, Wu, 2014). This is not adequate for a diagnostic 
biomarker. Clinically, a suspicion of CRC has to be 
already in place so that this biomarker can be applied 
and this application does not solve the issue of early 
detection for CRC. 
Perhaps an application for this biomarker in 
clinical practice would be the implementation of ccfDNA 
quantification in routine blood exams. That way, when 
altered, ccfDNA levels could indicate an early malignancy 
appearance or other diseases (Wang, Chen, Wu, 2014). 
Early disease investigation and an early treatment and 
management of the disease would then take place. 
After these considerations, an important need to 
establish the optimal DNA extraction method for ccfDNA 
quantification analysis remains, so that afterwards, clinical 
validation of the whole procedure could take place.
Integrity biomarkers
Two CRC studies analyzed DNA integrity using 
the ALU repeats and ACTB loci as targets. ALU repeats 
are the most abundant sequences in the human genome. 
TABLE I - Analytical Methods for the quantification of ccfDNA and other biomarkers in the CRC diagnosis
Type of biomarker Biomarker Analytical method Reference 
ccfDNA Quantification ccfDNA (ng/mL) qPCR Mouliére et al., 2014; Kondratov et 
al., 2014.
Fluorimetry (SybrGold) Czeiger et al., 2011
UV spectrophotometry Schwarzenbach et al., 2008
DNA DipStick Kit Frattini et al., 2008, Frattini et al., 
2006
Fluorimetry (Quant-iT™ 
PicoGreen®dsDNA Kit)
Heitzer et al., 2013
ccfDNA (alleles/mL) qPCR Spindler et al., 2015
MetDNA mGATA5 Qiagen Epitect Plus DNA 
bisulfite kit + MSP
Zhang et al., 2015
mSFRP2 Qiagen Epitect Plus DNA 
bisulfite kit + MSP
Zhang et al., 2015
mITGA4 Qiagen Epitect Plus DNA 
bisulfite kit + MSP
Zhang et al., 2015
mFOXE1 EpiTect Bisulphite Kit + MSP Melotte et al., 2015
mSYNE1 EpiTect Bisulphite Kit + MSP Melotte et al., 2015
mPPP1R3C Zymo EZ DNA Methylation Kit 
+ MSP
Takane et al., 2014
mEFHD1 Zymo EZ DNA Methylation Kit 
+ MSP
Takane et al., 2014
mSEPT9 Epi proColon Assay Church et al., 2014
Bisulfite conversion + Real time 
PCR 
deVos et al., 2009
mBCAT1 EpiTect Fast Bisulfite Conversion 
kit + MSP
Pedersen et al., 2015
mIKZF1 EpiTect Fast Bisulfite Conversion 
kit + MSP
Pedersen et al., 2015
ccfDNA Integrity ALU115 qPCR Hao et al., 2014
ALU247/ALU115 qPCR Hao et al., 2014
qPCR Yoruker et al., 2015
ACTB384 / ACTB106 qPCR Yoruker et al., 2015
ccfDNA: circulating cell free DNA; metDNA: methylated CRC genes; qPCR: quantitative polymerase chain reaction; MSP: methylation-specific 
polymerase chain reaction; ALU: Arthrobacter luteus; ACTB: beta-actin gene.
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ALU sequences are short interspersed elements (SINEs), 
typically 300 nucleotides, which account for more than 
10% of the genome. 
In the ALU real-time qPCR, a consensus sequence 
with abundant genomic ALU repeats was amplified and 
quantified. (Umetani et al., 2006). ACTB is a region of 
variable size located in the beta-actin (ACTB) gene, which 
is a single copy gene. The analytical method in both studies 
was qPCR (Table I).
ccfDNA has DNA fragments that vary in length. 
The integrity of ccfDNA has been widely studied and 
experimental studies with human CRC xenografts have 
revealed a high fragmentation (e.g. reduced integrity) of 
ccfDNA. However, with the patient’s samples, the results 
are inconsistent. Clinical studies on this subject have found 
increased DNA integrity but others have found a reduced 
DNA integrity (Yörüker et al., 2015).
Two studies (Hao et al., 2014; Yörüker et al., 
2015) evaluated integrity biomarkers. Both studies had 
a prospective design, used serum as a biological sample 
and both included all stages of CRC (Table III). The 
number of CRC patients was 205 for Hao et al. (2014) 
and 72 for Yörüker et al. (2015). The extraction methods 
were different from those used in the studies of ccfDNA 
quantification biomarkers.
Specific sizes of the ALU (115 and 247) and 
ACTB (106 and 384) loci were amplified by qPCR. The 
integrity index was calculated based on the ratio of DNA 
TABLE II - Clinical studies that evaluated the ccfDNA quantification as biomarker for the CRC diagnosis
Study design Subjects Tumor staging Biological sample
DNA extraction 
method 
ccfDNA levels  
(CRC vs 
controls)*
Sensibility / 
Specificity 
Reference
Prospective 
(Phase II)
223 CRC 
99 Healthy 
volunteers
Metastatic CRC Plasma
QIAsymphony 
virus/bacteria midi-
kit (Qiagen)
17900 
(800-4618400) vs 
2400 (800-14000) 
alelles/mL 
p<0.00001
ROC curve: 
AUC=0.949 
(95%CI 0.918-
0.968)
Spindler et al., 
2015
Prospective 
(clinical validation)
124 CRC 
71 Healthy 
volunteers
Metastatic (n=98) Plasma
QIAamp DNA 
purification kit 
(Qiagen)
Mean 26 ng/mL 
(n=124) vs  
4.7 ng/mL (n=71) 
 
p=0.0022(n=98)
ROC curve:  
AUC=0.91 (n=98) 
Moulière et al., 
2014
Prospective
20 CRC 
19 Healthy 
volunteers
Not informed Plasma 
Proba-NK DNA 
isolation kit (DNA-
Technology)
29.45 ± 12.24 vs 
7.07 ± 0.82 ng/mL, 
p<0.01***
Kondratov et al., 
2014
Prospective
32 CRC 
XX healthy 
volunteers
Stage IV Plasma
QIAamp DNA 
Blood Mini Kit or 
Qiagen Circulating 
Nucleic Acids Kit 
(Qiagen)
139.0 
(22.4-1.037.5) vs 
14.4 (12.2-19.5) ng/
mL, p<0.0001
Heitzer et al., 2013
Prospective 
(investigational)
38 CRC 
34 Healthy 
volunteers
Primary CRC Serum
No previous 
extraction 
798 ± 409 vs 308 
± 256 ng/mL, 
p<0.0001
42% / 94%** 
ROC curve: 
AUC=0.84 
(95%CI= 0.75-0.93
Czeiger et al., 2011
Prospective 
55 CRC 
20 Healthy 
volunteers 
Stage IV Serum
QIAamp DNA 
Mini Kit (Qiagen)
868 (22-3922) vs  
7 (5-16) ng/ml
Schwarzenbach et 
al., 2008
Prospective 
70 CRC 
20 Healthy 
volunteers
Primary and 
recurrent CRC 
Plasma
QIAamp Blood 
Extraction Kit 
(Qiagen)
437 (191-750) vs 
5 (5-15) ng/mL, 
p=0.001
Frattini et al, 2008
Prospective 
70 CRC 
20 healthy 
volunteers
All stages Plasma
QIAamp Blood 
Extraction Kit 
(Qiagen)
495 (100-1750) vs 
5 (5-50) ng/mL
Frattini et al, 2006
CRC: colorectal cancer; ccfDNA: circulating cell-free DNA; ROC: Receiver operating characteristic; AUC: area under the curve; 95%CI: 95% confidence interval; 
IQR: interquartil range ; * The results are shown as mean ± SD or median (IQR). **Cutoff value: 841 ng/mL..*** Upper cut-off value 17.7 ng/ml detected 8/20 CRC.
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quantification between the long and the short fragments 
(ALU247/ALU115 or ACTB384/ACTB106).
Hao et al. (2014) was able to provide significant 
results for a diagnostic biomarker, with high accuracy 
(AUC ROC curve 0.89) and good sensitivity (69.2%) 
and specificity (99.1%) (Table III) while Yörüker et al. 
(2015) achieved a borderline significance for the difference 
between patients and controls in both ALU247/ALU115 and 
ACTB384/ACTB106 integrity indexes. (Table III). 
Serum processing also affects the other biomarkers 
comprised in this review since a contaminated sample 
with genomic DNA leads to an imprecise quantity 
of ccfDNA which can diminish the sensibility of the 
gene mutation detection methods. In addition, the 
genomic DNA is less fragmented (higher integrity) than 
circulating DNA. This genomic DNA contamination can 
explain the divergent results encountered in both studies 
that evaluated ccfDNA integrity in this review. Hao et al. 
(2014) is based on the hypothesis that ccfDNA released 
from apoptotic cells is uniformly truncated into 185-200 
bp fragments and ccfDNA released from necrotic tumor 
cells varies in length, which may lead to an elevation of 
DNA with long fragments in serum or plasma (Hao et 
al., 2014). In contrast, Yörüker et al. (2015) was based 
on the information of experimental studies with human 
CRC xenografts that have revealed a high fragmentation 
(e.g. reduced integrity) of ccfDNA. Therefore, the 
genomic DNA contamination can enhance the results 
for Hao et al. (2014) and worsen the results for Yörüker 
et al. (2015). It is important to add that Hao et al. (2014) 
did a remarkable analysis for this diagnostic biomarker 
with all the parameters and presented good results, 
but still the choice of serum as a biological sample 
must matter.
Methylated biomarkers
The analytical method was different for each study 
that evaluated metDNA (Table I). Four used a commercial 
bisulfite conversion kit prior to the methylation specific 
PCR (MSP), one used a specific commercial kit that 
TABLE III - Clinical studies that evaluated the ccfDNA integrity and fragmentation as a biomarker for the CRC diagnosis
Study design Subjects
Tumor 
staging
Biological 
sample
DNA 
extraction 
method 
Biomarker 
Integrity 
(CRC vs 
controls)*
Sensibility / 
Specificity 
Other data Reference
Prospective 
(Investigational)
72 CRC 
42 Healthy 
volunteers 
All stages Serum
phenol/ 
chloroform 
extraction
ACTB384/
ACTB106 
0.12 vs 0.34, 
p=0.06 Yoruker et al., 
2015
ALU247/ALU115
0.03 vs 0.05, 
p>0.05
Prospective 
(Translational)
205 CRC 
110 Healthy 
volunteers 
All stages Serum
Magnetic 
Bead DNA 
Extraction Kit
ALU115
1046.0 (582.7-
1694.0) vs 
385.4 (205.7–
597.1) ng/mL, 
p<0.0001 
69.2% 
(95%CI= 59.4-
77.9) 
/99.1% 
(95%CI= 
95.0–99.9)** 
ROC curve 
AUC: 0.85 
(95%CI= 0.81-
0.91)
Accuracy=84.6%, 
VPP:98.6%, 
VPN=77.3%
Hao et al., 2014
ALU247/ALU115
0.62 (0.51-
0.65) vs 0.38 
(0.29-0.49), 
p<0.0001
73.1% 
(95%CI= 63.5-
81.3) / 97.3% 
(95%CI= 92.2-
99.4)*** 
ROC curve 
AUC: 0.89 
(95%CI= 0.85-
0.93)
Accuracy=85.5%, 
VPP=96.2%, 
VPN=79.3%
CRC: colorectal cancer; ACTB: beta-actin gene; ALU: 7short interspersed elements (SINEs) in the genome; ALU247/ALU115 and ACTB384/ACTB106: integrity indexes 
where the quantification of one size is divided by the quantification of the other size; 95%CI: 95% confidence interval; NPV: negative predictive value; PPV: positive 
predictive value; ROC: receiver operating characteristic; AUC: area under the curve.* Results are shown as mean ± SD or median (IQR). ** cut-off value=694 ng/
mL *** cutoff value=0.52; AUC: area under the curve.
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includes PCR and one applied real time PCR for analysis 
after the ccfDNA bisulfite conversion (Table I). 
All 6 studies had a prospective design. Of all of 
them, two were case-control studies. These studies 
selected 53-120 CRC patients and 47-1457 healthy 
subjects. There was no limit to tumor staging in 4 
studies, one had only carcinomas and the other had only 
asymptomatic CRC. All of the studies used plasma as 
the biological sample. A variety of commercial DNA 
extraction kits was found among the extraction method 
of the studies as seen above for ccfDNA quantification 
studies (Table I). Ten different methylated genes were 
assessed in this review (mGATA5, mSFRP2, mITGA4, 
mFOXE1, mSYNE1, mPPP1R3C, mEFHD1, mSEPT9, 
mBCAT1 and mIKZF1) (Table IV). 
The studies presented their results as either positivity 
or methylated frequency. In concept, both results presented 
the percentage of subjects positive for gene methylation 
in the study population and further on, will be referred 
to solely as methylation frequency. The methylation 
frequency for CRC patients ranged from 36.8% to 
81% and for controls from 3.5% to 19%. Three studies, 
comprising seven different genes, presented a significant 
difference between CRC and control groups (Table IV). 
Melotte et al. (2015) results are the combined analyses of 
two methylated genes mFOXE1 and mSYNE1. 
In total, the 6 studies provided 12 results regarding 
sensitivity and specificity (Table IV). Only Pedersen et al. 
(2015) provided a ROC curve analysis with AUC values 
of 0.807, 0.8135 and 0.8469 for mBCAT1, mIKZF1 and 
mBCAT1 or mIKZF1 methylated biomarkers, respectively. 
The remaining sensitivity values ranged from 42.9% to 
72% and specificity values ranged from 78% to 95%. 
Regarding the methylated biomarkers, the results 
for metDNA were less significant than the ones found 
for quantitative biomarkers in the CRC diagnosis, since 
a significant difference between CRC and control groups 
was achieved in 3 out of 6 studies for metDNA and 6 out 
of 9 studies for ccfDNA quantification. Also, the analysis 
of methylated genes presents a disadvantage for clinical 
practice, because it requires an additional step in the 
sample processing, the bisulfite conversion, thus it is one 
more variable to be validated in terms of repeatability and 
reproducibility implicating also in greater costs.
ccfDNA in CRC prognosis
Eleven studies assessed the CRC prognostic value 
of ccfDNA-based biomarkers, which are grouped in two 
categories: (i) ccfDNA quantification, and (ii) detection 
of gene mutations. 
As shown in Table V, seven studies measured 
ccfDNA levels as the prognosis biomarker, while eight 
studies detected mutations in CRC-related oncogenes 
(KRAS, BRAF and PIK3CA) and the tumor suppressor 
gene TP53. In clinical practice, the detection of mutations 
in these genes is associated with a worse prognosis.
Analytical methods
ccfDNA quantification was measured by three 
different PCR-based methods in five studies and by UV 
spectrophotometry in two studies. 
Gene mutations were detected in ccfDNA using five 
different technologies: BEAMing (2 studies) ARMS-PCR 
(2 studies), PNA-PCR (1 study), DNA sequencing (1 
study), and PCR-TGGE (1 study).
On the other hand, the majority (n=7) of studies that 
evaluated prognostic biomarkers limited their population 
to only metastatic CRC, which can be explained by the 
clinical trajectory of the CRC treatment (common surgical 
removal in colonoscopy for primary CRC) and the timing 
in disease that prognostic biomarkers can be clinically 
useful (Duffy, Crown, 2014).
Clinical studies characteristics
Two retrospective and nine prospective studies 
evaluated ccfDNA levels and gene mutations for the CRC 
prognosis. The sample population in these studies ranged 
from 25-503 CRC patients mainly in the metastatic stage 
(n=7) (Table VI). Only one in eleven studies used serum 
as a biological sample. 
The DNA extraction method analysis showed 
10 different types of methods. Interestingly, they were 
similar to the methods seen in studies for CRC diagnosis 
(Table VI). 
Considered prognostic parameters were progression 
free survival (PFS) and overall survival (OS). A few results 
were presented as Hazard Ratios (HR), which is the ratio 
between hazard rates of two conditions of an explanatory 
variable. Two different approaches for survival analysis 
with HR are present in this review. One approach 
represents a drug study where the treated population may 
die at half the rate per unit time as the control population. 
The hazard ratio would be 0.5, indicating lower hazard of 
death from the treatment. Whereas in another approach, 
the population bearing gene mutation may die two 
times more frequently per unit time than the wild type 
population, giving a hazard ratio of 2.
Gene mutations biomarkers for CRC prognosis
Eight studies investigated the mutations as biomarker 
for CRC prognosis using OS and/or PFS approaches and 
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TABLE IV - Clinical studies that evaluated the methylated biomarkers in the ccfDNA for the CRC diagnosis
Study design Subjects Tumor staging Biological sample
DNA extraction 
method Biomarker 
metDNA ***** 
(CRC vs 
controls)
Sensibility / Specificity Observations Reference
Prospective 
(Translational)
57 CRC  
47 Healthy 
volunteers
Carcino-mas Plasma QIAamp DNA Blood mini kit
mGATA5 Met: 63.4% vs 21.28% p<0.01
42.9% / 91.5% 
OR=8.06 
(95%CI=2.54-
25.5), p<0.01 Zhang X et 
al, 2015mSFRP2
Met: 54.4% vs 
27.7%, p<0.01
mITGA4 Met: 36.8% vs 19.2%, p=0.048
Prospective 
66 CRC 
240 
asymptomatic 
without 
detection 
All stages Plasma
QIAamp 
Circulating 
Nucleic Acid 
Test Kit
mFOXE1 
Combined 
Positivity 38/66 
(57%) vs 21/240 
(8.7%)
Combined analysis 58% 
(95%CI= 46-70%) / 91% 
(95%CI= 80-100%) * 
ROC curve 
AUC=0.70 
(95%CI= 0.69-
0.73)** Melotte V et 
al, 2015
mSYNE1
ROC curve 
AUC=0.72 
(95%CI=0.68-
0.75) **
Prospective 
(Case-control)
74 CRC 
144 Healthy 
volunteers
All stages Plasma
QIAamp 
Circulating 
Nucleic Acid Kit
mBCAT1 
Positivity: 65% 
(95%CI=0.4-
6.5) vs 3.5% 
(95% CI 54-76), 
p<0.0001
64.9 (95%CI=52.9-75.6) 
/ 96.5 (95%CI=92.1-
98.9)*** ROC curve AUC 
0.807(95% CI 0.7368-
0.8771)
Pedersen SK 
et al, 2015mIKZF1
Positivity: 68% 
(95%CI=57-
78) vs 4.9% 
(95%CI=1.3-
8.4), p<0.0001
67.6 (95%CI=55.7-78.0) / 
95.1 (95%CI=90.2-98.0)*** 
ROC curve AUC 0.8135 
(95% CI 0.7448-0.8822)
mBCAT1 or 
mIKZF1
77.0 (95%CI=65.8-86.0) / 
92.4(95%CI=86.7-96.4)*** 
ROC curve AUC 0.8469 
(95% CI 0.7848-0.9091)
Prospective 
(Investigational)
120 CRC 
96 Healthy 
volunteers
All stages Plasma
QIAamp 
Circulating 
Nucleic Acid Kit
mPPP1R3C Met: 81% vs 19%, p< 0,0001 81%/81%
Combined 
analysis: 
sensitivity 53% 
and specificity 
96%
Takane K et 
al, 2014
mEFHD1 Met: 62% vs 22%, p<0,0001 63%/78%
Prospective 
53 CRC 
1457 Non-
CRC
Asymptomatic Plasma
modified version 
of the 4.8-mL 
Chemagic viral 
DNA/RNA kit
mSEPT9 
Positivity 27/53 
(50.9%) vs 
126/1457 (8.6%)
48.2% (95%CI=32.4-
63.6%) / 91.5% 
(95%CI=89.7-93.1%)
PPV=5.2% 
(95%CI=3.5-
7.5%) and 
NPV=99.5% 
(95%CI=99.2-
99.6%)
Church TR et 
al, 2014
Prospective 
(Case-control)
90 CRC 
155 Healthy 
volunteers 
All stages Plasma
modified 
Chemagic viral 
DNA/RNA kit
mSEPT9
High sensitivity 
analysis: 65/90 
(72%) vs 22/155 
(14.1%)****
72% / 86% 
deVos T et al, 
2009
High specificity 
analysis : 50/90 
(55%) vs 7/155 
(4.5%)****
55% / 95%
Conditional 
qualitative 
analysis: 62/90 
(68%) vs 17/155 
(11%)****
69% / 89%
CRC: colorectal cancer; Met: methylation frequency; mGATA5, mSFRP2, mITGA4, mFOXE1, mSYNE1, mPPP1R3C, mEFHD1, mSEPT9, mBCAT1 and mIKZF1: commonly 
methylated genes in CRC; 95%CI: 95% confidence interval; NPV: negative predictive value; PPV: positive predictive value; ROC: receiver operating characteristic; AUC: 
area under the curve. * cutoff = zero;** ROC curve AUC results from the training set: 154 CRC and 444 controls; *** Threshold cut: any positive replicate out of three 
replicates;**** for each sample PCR was made 3 times. In the high sensitivity analysis sample were considered positive if at least one of the PCR reactions were positive. 
For the high specificity analysis samples were positive if at least 2 out of 3 were positive and the conditional qualitative analysis is a conditional algorithm further explained 
in the study deVos T, et al 2009; ***** See text for results details. The ROC curve analysis was found in 2 studies and the AUC values ranged from 0.70-0.84. The only 
methylated gene analyzed in more than one study was SEPT9 though with different analytical methods (Table IV). Based on sensitivity and specificity analysis, with the 
aid of ROC curve analysis, the most promising methylated biomarker in this review was the detection of mBCAT1 or mIKZF1 (Pedersen SK, 2015). Values for sensitivity 
and specificity were 77.0 (95%CI 65.8-86.0) and 92.4(95%CI 86.7-96.4) respectively, and the AUC value was 0.8469 (95% CI 0.7848-0.9091) for the ROC curve analysis.
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TABLE V - Analytical methods for the quantification of ccfDNA and other biomarkers in the CRC prognosis 
Biomarker Analytical method Reference 
ccfDNA quantification LINE-1 qRT-PCR Tabernero et al., 2015; Wong et al., 2015.
qPCR Spindler et al., 2015; Spindler et al., 2012.
Rt PCR Lin et al., 2014.
Spectrophotometry Schwarzenbach et al., 2008; Guadalajara et al., 
2008.
KRAS BEAMing Tabernero et al., 2015; Wong et al., 2015.
ARMS-qPCR Spindler et al., 2015; Spindler et al., 2013.
PNA-PCR Xu et al., 2014.
DxS kit Spindler et al., 2012.
Direct automatic sequencing Bazan et al., 2006.
Temperature gradient gel electrophoresis (TGGE) Lindforss et al., 2005.
PIK3CA BEAMing Tabernero et al., 2015; Wong et al., 2015.
BRAF BEAMing Tabernero et al., 2015; Wong et al., 2015.
ARMS-qPCR Spindler et al., 2013.
TP53 Direct automatic sequencing Bazan et al., 2006.
ccfDNA: circuating cell-free DNA; Rt: real-time; qPCR: quantitative polymerase chain reaction. 
TABLE VI - Characteristics of the clinical studies that evaluated gene mutation present in the ccfDNA and the ccfDNA quantification 
for the CRC prognosis
Study design Subjects Tumor staging Biological sample DNA extraction method Reference 
Retrospective 503 Metastatic CRC Plasma QIAamp DNA purification kit
Tabernero et al., 
2015 
Prospective (Open) 33 Refractory metastatic CRC Plasma
QIAamp DNA purification 
kit Wong et al., 2015
Prospective 
(Phase II) 211 Metastatic CRC Plasma
QIAsymphony virus/
bacteria midi-kit Spindler et al., 2015 
Retrospective 242 Metastatic CRC Plasma NucleoSpin® Plasma, N.740900 Xu et al., 2014
Prospective 
(Translational) 133 All stages Plasma
QIAamp DNA Tissue Kit 
and Minelute Virus Kit Lin et al., 2014
Prospective (Cohort) 95 Metastatic CRC Plasma
QIAsymphony virus/
bacteria midi-kit on a 
QIAsymphony robot
Spindler et al., 2013 
Prospective 
Investigational 108 Metastatic CRC Plasma
Automated QIAsymphony 
virus/bacteria midi-kit Spindler et al., 2012
Prospective Clinical 55 Stage IV Serum QIAamp DNA Mini Kit Schwarzenbach et al., 2008
Prospective 73 All stages Plasma QIAampTM kit Guadalajara et al., 2008
Prospective 50 Primary CRC Plasma Ultrasense Virus Kit Bazan et al., 2006
Prospective 25 Stages I, II and III Plasma Qiamp DNA Blood kit Lindforss et al., 2005
CRC: colorectal cancer.
I. B. D. Oliveira, R. D. C. Hirata
Braz. J. Pharm. Sci. 2018;54(1):e17368Page 10 / 14
seven studies assessed the general accordance in mutation 
detection between plasma and tissue (Table VII). All gene 
mutation analyses presented were made in ccfDNA.
KRAS
Tabernero et al. (2015), a drug study, used the hazard 
ratio (HR) between placebo and treatment groups for both 
OS and PFS showing a lower death rate in both mutated 
and wild type groups. However, the interaction p value 
between mutant and wild type groups was not significant 
for either OS or PFS (Table VII). 
Spindler et al. (2013) showed a significant difference 
between mutated and wild type groups both in OS and PFS 
and the HR was 2.26 for OS and 1.69 for PFS showing a 
bad prognosis in both analyses. Xu et al. (2014) analyzed 
only the OS and showed a significant difference between 
groups. Wong et al. (2015) analyzed only PFS and showed 
a significant difference between groups.
Three studies presented other results that did not fall 
into the OS and PFS analysis. Bazan et al. (2006) had a 
positive relationship between KRAS mutation and quicker 
disease relapse. On the other hand, Lindforss et al. (2015) 
did not correlate KRAS mutation with disease relapse. 
Spindler et al. (2012) correlated KRAS with ccfDNA 
quantification, but the difference between mutation and 
wild type groups was not significant. 
Overall concordance of KRAS mutation detection in 
plasma and tissue samples was evaluated in 8 studies. The 
values ranged from 56-85% (Table VII).
PIK3CA
One study (Tabernero et al., 2015) evaluated 
TABLE VII - Results for the detection of mutations in the ccfDNA for the CRC prognosis 
Biomarker
Overall survival Progression free survival
Mutation 
detection Reference
Mutation Wild type p value and HR Mutant Wild type p value and HR accordance 
KRAS HR= 0.81 
(95%CI=0.61-1.09)
HR= 0.67 
(95%CI 0.41–1.08)
p=0.56 HR= 0.51 
(95%CI 
0.40–0.65)
HR= 0.52 
(95%CI 
0.35–0.76)
0.74 76% Tabernero et al., 
2015 
105 (95%CI 58-
152 days) days
217 
(95%CI 76-358) 
days
p = 0.04 - Wong et al., 2015
85% Spindler et al., 
2015 
Median 15.7 
(95%CI 13.0-18.4) 
months
Median 19.1 
(95%CI 16.8-21.4) 
months
p = 0.009 177/242 (73%) Xu et al., 2014
Median 7.8 
(95%CI 4.6-8.4) 
months
Median 13.0 
(95%CI 9.5–15.1) 
months
HR= 2.26 
(95%CI 1.31-
3.90), P<0.0001
Median 2.7 
(95%CI 2.1–4.5) 
months
Median 4.6 
(95%CI 3.3–6.4) 
months
HR= 1.69 
(95%CI 1.03-
2.77), P=0.01
82% Spindler et al., 
2013
Median ccfDNA KRAS wild type 19500 (2000-4600000) vs KRAS mutant 25000 (2600-610000) alleles/ml p>0.05 
(not significant)*
90% Spindler et al., 
2012
KRAS mutations proved to be significantly related to quicker relapse (P <0.01)** 18/50 (36%) Bazan et al., 2006
The presence of KRAS in tissue or plasma did not correlate with disease relapse. Positivity 16/25 (64%)** 9/16 (56%) Lindforss et al., 
2005
PIK3CA HR= 0.84 
(95%CI 0.47-1.50) 
HR= 0.75 
(95%CI 0.57-0.99)
P=0.72 HR= 0.54 
(95%CI 
0.32–0.89)
HR= 0.50 
(95%CI 
0.40–0.63)
p=0.85 88% Tabernero et al., 
2015 
BRAF 97% Tabernero et al., 
2015 
 HR= 0.34 (95%CI 
0.09-1.19), 
p=0.003
HR= 0.29 (95%CI 
0.08–1.13), 
p=0.0006
100% Spindler et al., 
2013
TP53 Only a trend towards statistical significance was observed for the TP53 mutations (p= 0.083) Bazan et al., 2006
HR: hazard ratio; 95%CI: 95% confidence interval; ccfDNA: circulating cell-free DNA; NPV: negative predictive value; PPV: positive predictive value; *other data correlating 
ccfDNA with mutation analysis **other date regarding disease relapse; ***Sensitivity 78%; specificity 100%; PPV 100%; NPV 86%.
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PIK3CA mutation for CRC prognosis and there was 
no significant difference between mutant and wild type 
groups. The overall concordance between plasma and 
tissue in this study for PIK3CA gene was 88% (Table VII).
BRAF
One study (Spindler et al., 2013) had OS and 
PFS analysis for BRAF mutation. This study showed a 
significant difference between groups (p<0.05) and HR 
values (0.34 IC 95% 0.09–1.19 for OS and 0.29 IC 95% 
0.08–1.13 for PFS) showed a lower death rate and a better 
prognosis for the wild type group but these results were not 
significant considering the confidence interval analysis. 
(Table VII). Overall concordance in gene mutation 
detection between plasma and tissue for BRAF ranged 
from 97-100% (Table VII).
TP53
Unfortunately only a trend towards statistical 
significance (P = 0.083) was observed for the TP53 
mutations in one study (Table VII).
Regarding prognostic biomarkers, some studies 
justified the difference in gene mutation detection between 
plasma and tissue with the concept of tumor heterogeneity 
(Xu et al., 2014). Mutations present in the tumor may not 
be identified in the biopsy, since it is not always possible 
to extract and analyze the whole tumor mass, but they 
can appear in plasma analysis thanks to tumor-derived 
ccfDNA (Xu et al., 2014). Despite the small number of 
studies (n=2) BRAF seems to be the mutation in ccfDNA 
that better reflects tumor DNA content with 97% and 100% 
of overall accordance between plasma and tissue.
Regarding prognostic biomarkers, some studies 
justified the difference in gene mutation detection between 
plasma and tissue with the concept of tumor heterogeneity 
(Xu et al., 2014). Mutations present in the tumor may not 
be identified in the biopsy, since it is not always possible 
to extract and analyze the whole tumor mass, but they 
can appear in plasma analysis thanks to tumor-derived 
ccfDNA (Xu et al., 2014). Despite the small number of 
studies (n=2) BRAF seems to be the mutation in ccfDNA 
that better reflects tumor DNA content with 97% and 100% 
of overall accordance between plasma and tissue.
Results for ccfDNA quantification biomarkers
To obtain the results for CRC prognosis using 
ccfDNA quantification biomarkers, studies divided 
their groups into high ccfDNA content and low ccfDNA 
content. The threshold for dividing the patients between 
groups was the median value in 3 studies, (Tabernero et 
al., 2015; Lin et al., 2014; Spindler et al., 2012; Spindler 
et al., 2015) used the upper normal limit value (median 
plus two standard deviations = 7100 alleles/ml).
There were four studies with OS results and all of 
their findings showed that low ccfDNA content indicates 
better prognosis. Two of them presented quantitative 
values (Spindler et al., 2015; Spindler et al., 2012) 
measured in months and they both achieved statistically 
significant differences between groups.
The HR of 1.78 in Spindler et al. (2015) represented 
the risk for the high ccfDNA group, which indicates a 
worse prognosis for that group (Table VIII). The HR of 
0.31 in Tabernero et al. (2015) represents the risk for 
the low ccfDNA group indicating a better prognosis for 
that group. Lin et al. (2014) analysis for OS analysis 
were based on the survival rate in a follow-up period of 
5 years and there was a significant difference between 
high ccfDNA and low ccfDNA groups (p=0.001). In this 
study, the HR for the high ccfDNA group was 3.25 in the 
univariate analysis and 2.61 in the multivariate analysis. 
Two studies showed results for the PFS analysis. 
Tabernero et al. (2015) HR of 0.62 indicates a better 
prognosis for the low ccfDNA groups. Spindler et al. 
(2012) gave the results in quantitative data and the 
differencebetween high and low groups was statistically 
significant (Table VIII). 
Schwarzenbach et al. (2008) demonstrated that high 
ccfDNA content is correlated to a shorter survival (p=0.02) 
and Guadalajara et al. (2008) showed only a trend toward 
a worse prognosis for high ccfDNA content (Table VIII).
The validity of total ccfDNA quantification 
analysis as a biomarker may reside in prognosis. This 
review collected important results for this analysis 
where significant differences were found in OS and PFS 
analysis for patients with high and low ccfDNA content 
in plasma. In addition, the analytical technique qPCR 
and its derivatives seem to be a perfectly valid technique 
and has shown more relevant results in this review. 
Perhaps further studies on this subject can lead to the 
implementation of a new prognostic biomarker for CRC 
in clinical practice.
CONCLUSION
The lack of homogeneity in study designs and 
techniques is a challenge when comparing their results. 
It is difficult to choose a biomarker and analytical method 
to invest in for clinical validation. Nevertheless, few 
impressions lead the way for possible future research. 
The use of ccfDNA quantification in prognosis seems 
promising when analyzing the data obtained in this 
review. In addition to prognosis, ccfDNA quantification 
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can be used for treatment follow-up, prediction of 
recurrence or disease relapse and the sample collected 
for the prior purposes can be submitted to gene mutation 
detection, making ccfDNA a broad disease management 
biomarker. Results for the diagnostic value of ccfDNA 
were not so promising, however the combination of this 
biomarker with another existing biomarker should be 
considered: For example, Hao et al. (2014) studied the 
association of ALU115 detection, DNA integrity with 
ALU247/115 and CEA, which resulted in an accuracy 
of 91.59% showing how these biomarkers complement 
each other weakness. Still, it remains the need for a 
diagnostic method that can detect early occurrence 
of CRC is not. ccfDNA quantification as a diagnostic 
biomarker for CRC has promising results but it lacks 
clinical specificity since other diseases present a similar 
increase in ccfDNA content. However, the increasing 
research in the epigenomic field can lead the way to a 
clinically specific biomarker for CRC early diagnosis. As 
for an analytical method, qPCR and its derivatives seem 
to be a perfectly valid technique. The attempt to insert 
ccfDNA quantification into clinical practice may reside 
in prognosis using a qPCR technique. Further studies are 
needed to clinically validate this disease management 
method in terms of repeatability, reproducibility and 
other clinically relevant parameters.
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